Top Markets
Coin of the day
Cardiol Therapeutics Inc. Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

CRDL
Clasificación en acciones #17188
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company,... Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Precio por acción
$2.20
Última sincronización: 2026-09-01
Capitalización bursátil
$253.81M
Cambio (1 día)
10.29%
Cambio (1 año)
99.67%
País
CA
Comercio Cardiol Therapeutics Inc. (CRDL)

Categoría

Ganancias de Cardiol Therapeutics Inc. (CRDL)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Cardiol Therapeutics Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Cardiol Therapeutics Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras